ArticlePloS one2025
Cohort-resolved excess mortality in Germany (2000-2024): Patterns and implications for the SARS-CoV-2 era.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the impact of the SARS-CoV-2 pandemic on mortality requires more than aggregate statistics. While whole-population indicators have informed policy, they risk concealing subgroup-specific patterns. We analysed all-cause mortality in Germany from 2000 to 2024 using a weekly, cohort-resolved framework across 15 age groups to detect excess and under-mortality before, during, and after the pandemic. Expected mortality was modelled using exponential trends from two decades of pre-pandemic data. Deviations from expectation were quantified as normalised excess all-cause mortality rates (NEAMR), enabling the identification of significant, age-specific anomalies. We found sustained NEAMR in adults aged 75-79 and 35-49 from late 2021 through 2024-patterns absent in whole-population trends. Conversely, cohorts aged 30-34 and 55-59 showed persistent under-mortality. Earlier excess peaks in older cohorts (e.g., 85-89 in 2003, 95+ in 2013) suggest generational vulnerabilities potentially linked to early-life adversity. Cross-correlation analyses indicate that associations between NEAMR and SARS-CoV-2 mRNA injection rates diverge from expected protective patterns in most age cohorts, especially during the 2021 'alpha-to-delta' transition. These findings highlight the need for further hypothesis-driven investigations as well as a high-resolution mortality surveillance. Cohort-resolved analysis reveals NEAMR signals that aggregate data obscure, offering a more accurate assessment of public health outcomes across demographic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.